arrow
A

Amy E. Armstrong

Washington University in St. Louis
H指数:17
被引数:1,739

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A framework for prioritizing novel agents in malignant peripheral nerve sheath tumor trials: A report from the neurofibromatosis clinical trials consortium

恶性外周神经鞘瘤临床试验中新型药物优先级评估框架:神经纤维瘤临床试验联盟的报告

2026-08-180
PRE
Patient Utilization and Satisfaction of Supportive Skin Care Products Among Children with Cancer Receiving Mitogen-Activated Protein Kinase Pathway Inhibitors

接受丝裂原活化蛋白激酶通路抑制剂治疗的儿童癌症患者对支持性皮肤护理产品的使用情况与满意度

2026-05-010
PRE
Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions

entrectinib在颅外实体或中枢神经系统 (CNS) 肿瘤携带NTRK或ROS1融合的儿童中的疗效和安全性

2025-02-010
OAAI
Post-progression survival outcomes in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial who received follow-up immunotherapy

ENGOT-EN6-NSGO/GOG-3031/RUBY试验中接受随访免疫治疗的局部晚期或复发性子宫内膜癌(pA/rEC)患者的术后进展生存结局。

2024-09-010
PRE
Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics
2024-08-020
OAAI
EFFICACY AND SAFETY OF ENTRECTINIB IN CHILDREN WITHNTRK ORROS1 FUSION-POSITIVE (FP) PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS
2024-06-180
OAAI
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)
2022-04-0856
OAAI
Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial

卡博替尼治疗1型神经纤维瘤病相关的丛状神经纤维瘤: 一项2期试验

2021-01-1348
OA